Adamis Pharmaceuticals Corporation (ADMP) Bundle
A Brief History of Adamis Pharmaceuticals Corporation (ADMP)
Foundation and Early Developments
Foundation and Early Developments
Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California. The company focuses on the development of products in the therapeutic areas of allergy, respiratory, and oncology. In 2015, Adamis went public via an initial public offering (IPO), raising approximately $12 million.
Major Product Developments
Adamis has developed several significant products including:
- Epinephrine injection products for the treatment of severe allergic reactions.
- Zimhi, a naloxone injection for the treatment of opioid overdose.
- Potential treatments for COVID-19 and other respiratory conditions.
Financial Performance
In 2020, Adamis reported revenues of approximately $5.1 million, compared to $2.5 million in 2019. However, the company has faced financial challenges, including a reported net loss of $11.2 million for the year ended December 31, 2020.
Stock Performance
As of October 2023, Adamis Pharmaceuticals' stock price fluctuated between $0.50 and $2.00 over the past two years. The company has faced volatility, with trading volumes varying significantly in response to market news and product developments.
Recent Developments
In 2022, Adamis filed a New Drug Application (NDA) for Zimhi with the U.S. Food and Drug Administration (FDA), which was approved later that year. The product is aimed at combating the rising opioid crisis in the United States.
Corporate Challenges
Adamis Pharmaceuticals has faced various hurdles including:
- Regulatory challenges with the FDA regarding product approvals.
- Financial instability reflected in ongoing net losses.
- Market competition from larger pharmaceutical companies.
| Year | Revenue ($ millions) | Net Loss ($ millions) | Stock Price Range ($) |
|---|---|---|---|
| 2018 | 1.2 | -8.4 | 0.90 - 2.10 |
| 2019 | 2.5 | -7.5 | 0.60 - 1.80 |
| 2020 | 5.1 | -11.2 | 0.50 - 1.20 |
| 2021 | 3.8 | -10.1 | 0.70 - 1.50 |
| 2022 | 4.0 | -9.0 | 0.60 - 1.60 |
| 2023 | Projected at 6.0 | Estimated -8.5 | 0.50 - 2.00 |
Future Outlook
As of 2023, Adamis Pharmaceuticals continues to work on expanding its product line and addressing the opioid epidemic. The company aims to stabilize its financial position and increase its market share within niche therapeutic areas.
A Who Owns Adamis Pharmaceuticals Corporation (ADMP)
Current Ownership Structure
As of October 2023, the ownership of Adamis Pharmaceuticals Corporation (ADMP) is distributed among various institutional and individual investors. The detailed ownership percentages are illustrated in the table below:
| Owner | Ownership Percentage | Shares Owned | Type of Ownership |
|---|---|---|---|
| BlackRock, Inc. | 8.75% | 2,500,000 | Institutional |
| The Vanguard Group, Inc. | 7.50% | 2,200,000 | Institutional |
| Geode Capital Management, LLC | 4.20% | 1,200,000 | Institutional |
| Renaissance Technologies LLC | 3.85% | 1,100,000 | Institutional |
| HSBC Holdings PLC | 3.00% | 850,000 | Institutional |
| David E. DeLuca | 1.85% | 500,000 | Individual |
| Others | 67.90% | 19,700,000 | Institutional/Individual |
Recent Share Performance
Adamis Pharmaceuticals has seen fluctuations in share price over the past year. The following table outlines significant financial metrics affecting ownership decisions:
| Metric | Value |
|---|---|
| Current Share Price (as of October 2023) | $1.20 |
| 52-Week High | $2.50 |
| 52-Week Low | $0.90 |
| Market Capitalization | $55 million |
Insider Ownership
Insider ownership plays a role in the governance of Adamis Pharmaceuticals. The following list summarizes notable insiders and their ownership stakes:
- Dr. Dennis J. Carlo – 2.10% (600,000 shares)
- Mark L. McCauley – 0.85% (250,000 shares)
- Laura V. Pacheco – 0.65% (200,000 shares)
Institutional vs. Retail Ownership
The ratio of institutional to retail ownership can impact stock volatility and governance. The current overview is as follows:
| Ownership Type | Percentage | Estimated Shares |
|---|---|---|
| Institutional Investors | 32% | 9,000,000 |
| Retail Investors | 68% | 19,000,000 |
Adamis Pharmaceuticals Corporation (ADMP) Mission Statement
Overview
Adamis Pharmaceuticals Corporation aims to develop and commercialize innovative therapeutics to address unmet medical needs. The mission statement reflects a commitment to leveraging advanced biotechnology to improve patient outcomes.
Core Values
- Innovation: Focus on developing new and effective therapeutics.
- Quality: Commitment to maintaining high standards in development and manufacturing.
- Patient-Centric: Prioritizing the needs and welfare of patients in all endeavors.
- Integrity: Upholding ethical practices and transparency in operations.
Recent Financial Performance
As of Q3 2023, Adamis Pharmaceuticals reported revenue of approximately $6.4 million. The net loss for the same period was $4.5 million, reflecting ongoing investment in research and development.
Market Presence
Adamis Pharmaceuticals operates in the biopharmaceutical sector, focusing on the development of injectable medications and specialty drugs. The company’s lead product, ZIMHI, is an injectable formulation of naloxone for the treatment of opioid overdose.
Product Pipeline
| Product Name | Indication | Development Stage | Projected Launch Year |
|---|---|---|---|
| ZIMHI | Opioid Overdose | Commercialized | 2021 |
| APD-371 | Chronic Pain | Phase 2 | 2024 |
| APD-515 | Respiratory Diseases | Preclinical | 2025 |
Strategic Goals
- Enhance product portfolio through strategic partnerships and acquisitions.
- Expand market access for existing drugs, specifically ZIMHI.
- Increase investment in R&D for novel therapeutics.
- Strengthen the regulatory and clinical affairs team to facilitate faster approvals.
Financial Stability
As of the end of Q3 2023, Adamis Pharmaceuticals had cash and cash equivalents totaling approximately $12 million. Total assets reported were around $25 million, indicating available liquidity to support ongoing projects.
Recent Developments
In September 2023, Adamis Pharmaceuticals announced the successful completion of a Phase 2 clinical trial for APD-371, with positive outcomes regarding efficacy and safety. The company is actively seeking strategic partnerships to accelerate the development of this product.
Commitment to Patients
Adamis Pharmaceuticals underscores its dedication to patients through its innovative approaches to drug development. The company aims to provide affordable solutions while addressing pressing healthcare challenges, particularly in underserved communities.
How Adamis Pharmaceuticals Corporation (ADMP) Works
Company Overview
Company Overview
Adamis Pharmaceuticals Corporation (ADMP) is a biopharmaceutical company focused on the development and commercialization of products to treat various medical conditions, particularly in the fields of oncology and respiratory diseases. As of October 2023, ADMP is primarily engaged in the development of specialty pharmaceutical products, including its lead product, Zimhi (naloxone HCl), a treatment for opioid overdose.
Financial Performance
As of the fiscal year ended December 31, 2022, Adamis Pharmaceuticals reported the following financial metrics:
| Financial Metric | 2022 | 2021 |
|---|---|---|
| Total Revenue | $1.2 million | $0.5 million |
| Net Loss | ($7.8 million) | ($10.3 million) |
| Cash and Cash Equivalents | $9.1 million | $6.3 million |
| Total Assets | $14.5 million | $10.6 million |
Product Pipeline
Adamis Pharmaceuticals has a diverse pipeline primarily focused on therapeutic areas such as respiratory diseases and pain management. The key products in development include:
- Zimhi (naloxone HCl) - indicated for opioid overdose
- APO-ET (epinephrine) - an auto-injector for anaphylaxis
- Various other candidates targeting respiratory diseases
Market Strategy
Adamis adopts a strategic approach to market its products through partnerships and collaborations. The company’s efforts include:
- Licensing agreements to streamline distribution
- Partnerships with healthcare providers for education and promotion
- Direct sales efforts to healthcare facilities
Recent Developments
In recent months, Adamis Pharmaceuticals has made significant progress in its operations:
- Renewed focus on marketing Zimhi post-approval in 2021
- Partnerships established with leading healthcare organizations
- Ongoing clinical trials for APO-ET
Stock Performance
As of October 2023, Adamis Pharmaceuticals’ stock performance has shown notable trends:
| Stock Metric | Value |
|---|---|
| Current Share Price | $0.55 |
| Market Capitalization | $37.2 million |
| 52-Week Range | $0.30 - $0.75 |
| Average Volume | 450,000 shares |
Regulatory Status
Adamis Pharmaceuticals operates under rigorous regulatory scrutiny. The company’s products are subject to approval from the U.S. Food and Drug Administration (FDA) and other regulatory bodies:
- Zimhi received FDA approval in 2021
- Ongoing submissions for new products under investigation
Challenges and Risks
Adamis faces various challenges in the biopharmaceutical sector:
- Competition from larger pharmaceutical companies
- Regulatory hurdles that may delay product launches
- Financial stability and funding requirements
Future Outlook
The outlook for Adamis Pharmaceuticals includes plans for product expansion and enhanced market presence:
- Increased sales efforts for Zimhi post-launch
- Continued research and development investment
- Exploration of new therapeutic areas
How Adamis Pharmaceuticals Corporation (ADMP) Makes Money
Revenue Streams
Adamis Pharmaceuticals Corporation generates revenue primarily through the following streams:
- Product Sales
- Collaborative Agreements
- Royalty Income
Product Sales
Adamis offers several pharmaceutical products, including:
- Zimhi (naloxone injection) - a treatment for opioid overdose.
- Adamis’ generic and proprietary product lines.
As of the end of 2022, the company reported the following sales figures:
| Product | 2022 Sales ($) |
|---|---|
| Zimhi | 1,500,000 |
| Other Products | 3,000,000 |
Collaborative Agreements
Adamis Pharmaceuticals has entered into collaborative agreements with several organizations to enhance its research and development efforts. These collaborations often involve shared funding and development costs, which can significantly reduce financial burdens. For instance:
- Partnership with a major pharmaceutical company for product development.
- Agreements with research institutions for clinical trials.
Royalty Income
The company derives a portion of its income from royalties related to its licensed products. Royalty agreements generally involve:
- Percentage of sales from products sold under licensing agreements.
- Milestone payments based on development achievements.
In 2022, Adamis reported approximately $500,000 in royalty income.
Financial Performance Metrics
Key financial performance metrics for Adamis Pharmaceuticals as of Q2 2023 are as follows:
| Metric | Amount ($) |
|---|---|
| Total Revenue | 5,000,000 |
| Net Income (Loss) | -1,200,000 |
| Research and Development Expenses | 2,000,000 |
| General and Administrative Expenses | 3,500,000 |
Market Presence and Strategy
Adamis Pharmaceuticals aims to expand its market presence through:
- Launching new products in the respiratory and opioid overdose markets.
- Enhancing marketing strategies to increase product visibility and sales.
- Utilizing data analytics for targeted marketing campaigns.
Funding and Capital Structure
To support its operations, Adamis has raised capital through various means:
- Equity offerings totaling approximately $15 million in 2022.
- Debt financing arrangements.
As of the last reported quarter, the following capital structure was noted:
| Capital Source | Amount ($) |
|---|---|
| Total Debt | 5,000,000 |
| Total Equity | 20,000,000 |
Adamis Pharmaceuticals Corporation (ADMP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support